Search results
30 lis 2020 · III. What Are the Preferred Treatment Regimens for Babesiosis? Recommendation: We recommend treating babesiosis with the combination of atovaquone plus azithromycin or the combination of clindamycin plus quinine (strong recommendation, moderate-quality evidence).
13 lut 2024 · Treatment options. For ill patients, treatment usually involves at least a 7- to 10-day course of two prescription medications; often the duration of treatment is longer in immunocompromised patients. The typical combinations are: atovaquone PLUS azithromycin (preferred) clindamycin PLUS quinine* (alternative)
3 sty 2024 · Drug-resistant babesiosis may respond to a novel combination therapy, researchers say. The treatment, which involves the antimalarial drug tafenoquine and the anti-fungal/anti-parasite drug atovaquone, may also provide immunity against future babesiosis infections.
16 lis 2000 · For the treatment of babesiosis, a regimen of atovaquone and azithromycin is as effective as a regimen of clindamycin and quinine and is associated with fewer adverse reactions....
21 cze 2012 · This review article discusses the epidemiology, transmission, clinical manifestations, parasite life cycle, immunology, diagnosis, and treatment of babesiosis, a tickborne zoonosis.
17 cze 2021 · Due to the large diversity of Babesia species and their vertebrate hosts, a broad-spectrum-activity drug is ideal in treating babesiosis (4). Babesiosis is usually treated for 7 to 10 days with high doses of a combination of either atovaquone and azithromycin or clindamycin and quinine (5).
Babesiosis is a zoonotic disease of humans caused by the hemoprotozoan piroplasm parasite “ Babesia.” The primary reservoir hosts are usually the rodents, primarily the white-footed mice.
